The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program. “This recommendation is outside of the scope of MedPAC’s mission, lacks a clear purpose and penalizes certain hospitals for their ability to obtain discounts on the items and services they purchase,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development. “The AHA strongly urges MedPAC to withdraw this draft recommendation and, instead, to undertake an analysis of the trend of rapidly increasing drug prices, which presents the Medicare program and its beneficiaries with remarkable challenges.” MedPAC expects to vote on payment recommendations for fiscal year 2017 later this week.

Related News Articles

Headline
The AHA today urged the Centers for Medicare…
Headline
The AHA Friday shared recommendations for developing a unified post-acute care prospective payment system as required by the Improving Medicare Post-Acute Care…
Insights and Analysis
As the 2019 chair of the AHA’s Section for Small or Rural Hospitals, I can attest that AHA is stepping up in a big way to grapple with the issues that affect…
Headline
The Centers for Medicare…
Headline
The Department of Health and Human Services’ Center for Medicare and Medicaid Innovation today announced a new payment model for emergency ambulance services…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…